{"id":488,"date":"2025-02-25T17:00:25","date_gmt":"2025-02-25T21:00:25","guid":{"rendered":"https:\/\/blogs.duanemorris.com\/lifescienceslaw\/?p=488"},"modified":"2025-02-25T17:00:26","modified_gmt":"2025-02-25T21:00:26","slug":"first-circuit-embraces-more-restrictive-view-of-false-claims-act-kickback-enforcement-provision","status":"publish","type":"post","link":"https:\/\/blogs.duanemorris.com\/lifescienceslaw\/2025\/02\/25\/first-circuit-embraces-more-restrictive-view-of-false-claims-act-kickback-enforcement-provision\/","title":{"rendered":"First Circuit Embraces More Restrictive View of False Claims Act Kickback Enforcement Provision"},"content":{"rendered":"\n<p><strong>By: <a href=\"https:\/\/www.duanemorris.com\/attorneys\/danielrwalworth.html\">Daniel R. Walworth<\/a>,\u00a0<a href=\"https:\/\/www.duanemorris.com\/attorneys\/christopherhcasey.html\">Christopher H. Casey<\/a>,\u00a0<a href=\"https:\/\/www.duanemorris.com\/attorneys\/frederickrball.html\">Frederick R. Ball<\/a>,\u00a0<a href=\"https:\/\/www.duanemorris.com\/attorneys\/erinmduffy.html\">Erin M. Duffy<\/a> and <a href=\"https:\/\/www.duanemorris.com\/attorneys\/josephwelsh.html\">Joseph R. Welsh<\/a><\/strong><\/p>\n\n\n\n<p>The United States Court of Appeals for the First Circuit\u2019s opinion in <em>United States v. Regeneron Pharmaceuticals, Inc.<\/em> has sharpened the circuit split for demonstrating the effect of a kickback on healthcare decisions under the False Claims Act (FCA). The Regeneron court held that an FCA claim based on an alleged violation of the Anti-Kickback Statute requires demonstrating that an alleged unlawful kickback was the \u201cbut-for\u201d cause of a submitted claim.<\/p>\n\n\n\n<p><a href=\"https:\/\/www.duanemorris.com\/alerts\/first_circuit_embraces_more_restrictive_false_claims_act_kickback_enforcement_provision_0225.html\">Read the full story on the Duane Morris LLP website<\/a>.<\/p>\n\n\n\n<p><\/p>\n","protected":false},"excerpt":{"rendered":"<p>By: Daniel R. Walworth,\u00a0Christopher H. Casey,\u00a0Frederick R. Ball,\u00a0Erin M. Duffy and Joseph R. Welsh The United States Court of Appeals for the First Circuit\u2019s opinion in United States v. Regeneron Pharmaceuticals, Inc. has sharpened the circuit split for demonstrating the effect of a kickback on healthcare decisions under the False Claims Act (FCA). The Regeneron &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/blogs.duanemorris.com\/lifescienceslaw\/2025\/02\/25\/first-circuit-embraces-more-restrictive-view-of-false-claims-act-kickback-enforcement-provision\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;First Circuit Embraces More Restrictive View of False Claims Act Kickback Enforcement Provision&#8221;<\/span><\/a><\/p>\n","protected":false},"author":6,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[2],"tags":[341,119],"ppma_author":[521],"class_list":["post-488","post","type-post","status-publish","format-standard","hentry","category-general","tag-false-claims-act","tag-rick-ball"],"authors":[{"term_id":521,"user_id":6,"is_guest":0,"slug":"duanemorris3","display_name":"Duane Morris","avatar_url":"https:\/\/secure.gravatar.com\/avatar\/843ff6e7a8fe5fc92109b47a45f34b6cf0ea499e6e788db23456c838b0ae6747?s=96&d=blank&r=g","0":null,"1":"","2":"","3":"","4":"","5":"","6":"","7":"","8":""}],"_links":{"self":[{"href":"https:\/\/blogs.duanemorris.com\/lifescienceslaw\/wp-json\/wp\/v2\/posts\/488","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/blogs.duanemorris.com\/lifescienceslaw\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/blogs.duanemorris.com\/lifescienceslaw\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/blogs.duanemorris.com\/lifescienceslaw\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/blogs.duanemorris.com\/lifescienceslaw\/wp-json\/wp\/v2\/comments?post=488"}],"version-history":[{"count":0,"href":"https:\/\/blogs.duanemorris.com\/lifescienceslaw\/wp-json\/wp\/v2\/posts\/488\/revisions"}],"wp:attachment":[{"href":"https:\/\/blogs.duanemorris.com\/lifescienceslaw\/wp-json\/wp\/v2\/media?parent=488"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/blogs.duanemorris.com\/lifescienceslaw\/wp-json\/wp\/v2\/categories?post=488"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/blogs.duanemorris.com\/lifescienceslaw\/wp-json\/wp\/v2\/tags?post=488"},{"taxonomy":"author","embeddable":true,"href":"https:\/\/blogs.duanemorris.com\/lifescienceslaw\/wp-json\/wp\/v2\/ppma_author?post=488"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}